Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.-Reference-Cited by-同舟云学术

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Published:2021 Issue: Volume:16 Page:100284
ISSN:2213-0489
Container-title:Leukemia Research Reports
language:en
Short-container-title:Leukemia Research Reports

Author:

Devi Kanta,Shaikh Muhammad Usman,Ali Natasha Bahadur,Adil Salman Naseem,Khan Maria,Soomar Salman Muhammad

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference20 articles.

1. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Vitolo;Ann. Oncol.,2016

2. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease;Chapuy;Blood, J. Am. Society of Hematol.,2016

3. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood, J. Am. Society of Hematol.,2015

4. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment;Liu;Am. J. Hematol.,2019

5. Report of an international network of cancer treatment and research workshop on non-hodgkin's lymphoma in developing countries;Naresh;Blood Cells, Molecules, and Diseases,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital;MD-Onco;2024-06-14

2. Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana;Biomedicines;2024-01-25

3. Independent predictors of mortality and 5-year trends in mortality and resource utilization in hospitalized patients with diffuse large B cell lymphoma;Baylor University Medical Center Proceedings;2023-10-23

4. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis;Clinical Lymphoma Myeloma and Leukemia;2022-10

5. Extranodal primary CD20-negative diffuse large B-cell lymphoma with cytoplasmic p16 expression;Biomedical Research and Therapy;2022-06-30